NCT05491356View on ClinicalTrials.gov

Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

March 30, 2024

Study Completion Date

May 30, 2024

Conditions
Hematoma, SubduralFibrinolytic; Hemorrhage
Interventions
DRUG

Tissue Plasminogen Activator

Dosage of 1mg/mL mixed in 0.9% saline solution, intra-catheter administration, sterile

DRUG

Placebo

0.9% saline solution, intra-catheter administration, sterile

Trial Locations (1)

L8L 2X2

Hamilton General Hospital, Hamilton

All Listed Sponsors
lead

Hamilton Health Sciences Corporation

OTHER

NCT05491356 - Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas | Biotech Hunter | Biotech Hunter